and holds, a technical bounce toward ~6.36 becomes more plausible.
Neutral/Negative Catalysts
often attracts sell-the-rip behavior.
Financial Performance
Financial data not available in the provided snapshot (error: list index out of range), so latest quarter growth trends and latest quarter season cannot be assessed from the given data.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent rating/target trend: Single notable update—Citizens initiated coverage (2025-12-18) with Outperform and a $19 price target.
Wall Street pro view (pros): Large/compelling TAM for needle-free epinephrine; platform approach (Nasax); potential best-in-class product positioning.
Wall Street pro view (cons): Limited breadth of analyst inputs in provided data (only one initiation); without incremental catalysts/news, the stock can continue to trade on technical pressure rather than fundamentals.
Wall Street analysts forecast NSRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSRX is 19 USD with a low forecast of 19 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NSRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSRX is 19 USD with a low forecast of 19 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.400
Low
19
Averages
19
High
19
Current: 5.400
Low
19
Averages
19
High
19
Citizens
Outperform
initiated
$19
AI Analysis
2025-12-18
Reason
Citizens
Price Target
$19
AI Analysis
2025-12-18
initiated
Outperform
Reason
Citizens initiated coverage of Nasus Pharma with an Outperform rating and $19 price target. The firm says the company uses its Nasax platform to develop dry powder-based intranasal therapies for emergency medical conditions. The opportunity for needle-free alternatives to epinephrine autoinjectors like the EpiPen is "large and compelling," and the introduction of multiple needle-free alternatives will drive a majority market share in coming years, the analyst tells investors in a research note. Citizens believes Nasus Pharma's NS002 has the potential to be the "best-in-class" nasal spray epinephrine.
Laidlaw
Yale Jen
Buy
initiated
$22
2025-09-29
Reason
Laidlaw
Yale Jen
Price Target
$22
2025-09-29
initiated
Buy
Reason
Laidlaw analyst Yale Jen initiated coverage of Nasus Pharma with a Buy rating and $22 price target. The firm says Nasus is a mid-clinical stage biotech company focusing on the development of NS-002, a \"well differentiated\" powder-based intranasal anaphylaxis treatment. The \"compelling\" NS-002 in anaphylaxis Phase II study outcomes bode well for a successful Phase III study and potential approval as the first powder-based intranasal anaphylaxis therapy, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NSRX
